Rhone-poulenc Rorer Pharmaceuticals Inc.

Rhone-poulenc Rorer International (holdings), Inc.

Christopher Cheadle

Victoria J South

George A Ricca

Joseph Schlessinger

Michael C Jaye

Richard M Kris

Yuri D Ivashchenko

George H Searfoss, Iii

Stephen M French

Francoise Bellot

David Givol

Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.

Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same

This invention provides a unique SH3 binding domain core motif of the sequence RPLPXXP and cDNA clones encoding proteins which interact with the SH3 domain of c-src, as well as the amino acid sequences which mediate this binding. Another embodiment of this invention is a method of identifying SH3-binding proteins and elucidating the sequences which mediate binding. This method may be used as an assay to select compounds which bind to this site and which inhibit or enhance the binding of the SH3 domain.

Expression cloning of c-src SH3-domain binding proteins

Growing community of inventors

West Chester, PA, United States of America

Christopher Cheadle